stx107
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2009 (NCT00965432)
Timeline
Indications
Mechanism of action
- Metabotropic glutamate receptor 5NEGATIVE ALLOSTERIC MODULATOR
GRM5 negative allosteric modulator
Chemistry & pharmacology
Loading structure…
SMILES
CC1=NC(=CS1)C#CC2=CN=C(C=C2)C3=CC(=CC(F)=C3)C#N- Mol. weight
- 319.356 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- NCATSO55CA1TU5D ↗
- ChEMBLCHEMBL3642985 ↗
- ChEMBLCHEMBL3545037 ↗
Also known as
- stx107
- stx107
- stx-107
- stx-107
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01896843 | Phase 1 | Jun 27, 2013 | National Institute of Mental Health (NIMH) |
| NCT01325740 | Phase 2 | May 1, 2011 | Seaside Therapeutics, Inc. |
| NCT00965432 | Phase 1 | Sep 1, 2009 | National Institutes of Health (NIH), Seaside Therapeutics, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Seaside Therapeutics, Inc. | For profit | 2 | 2 | 2 | 2009 |
| National Institute of Mental Health (NIMH) | Government | 1 | 1 | 1 | 2013 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2009 |
3 organizations
Page 1 / 1